Immuron (IMRN) Cash from Financing Activities (2016 - 2024)
Immuron (IMRN) posted quarterly Cash from Financing Activities of -$29591.5 for Q4 2024, down 27.71% year-on-year from -$40937.2 in Q1 2024, and down 27.71% on a QoQ basis from -$23170.0 in Q4 2023.
Immuron (IMRN) Cash from Financing Activities (2016 - 2024) Analysis & Trends
Immuron (IMRN) has reported Cash from Financing Activities for 8 consecutive years, with -$29591.5 the latest figure, recorded in Q4 2024.
- Quarterly Cash from Financing Activities fell 27.71% year-over-year to -$29591.5 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$72829.2 (down 100.27% YoY) and the FY2025 annual result came in at $199747.0, up 23994.93% from the prior year.
- Cash from Financing Activities fell to -$29591.5 in Q4 2024 per IMRN's latest filing, from -$23170.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for IMRN reached as high as $26.6 million in Q4 2020 and fell as low as -$29591.5 in Q4 2024.
- A 5-year average of $5.3 million and a median of -$21495.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2020 — Cash from Financing Activities jumped 2007.11% — and 2022, when it tumbled 1606.01%.
- Year by year, Cash from Financing Activities stood at $26.6 million in 2020, then tumbled by 99.99% to $1427.3 in 2021, then slumped by 1606.01% to -$21495.0 in 2022, then decreased by 7.79% to -$23170.0 in 2023, then slipped by 27.71% to -$29591.5 in 2024.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$29591.5, -$23170.0, and -$21495.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -29,591.52 |
| Dec 31, 2024 | -29,591.52 |
| Dec 31, 2023 | -23,170.00 |
| Dec 31, 2023 | -23,170.00 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2021 | 1,427.28 |
| Dec 31, 2021 | 1,427.28 |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2017 | -245,884.00 |
| Dec 31, 2017 | -245,884.00 |
| Dec 31, 2016 | 2.14 Mn |
| Dec 31, 2016 | 2.14 Mn |